Podcasts about HIV

This week, Marianna sits down with John Faragon to talk about the most recent changes to the DHHS HIV Guidelines. Tune in to find out the latest in antiretroviral therapy, initiating treatment, HBV coinfection, and more. -- Help us track the number of listeners our episode gets by filling out this brief form!  (https://www.e2NECA.org/?r=EPP8742)--Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. --Check out our free online courses: https://www.necaaetc.org/self-paced-courses--Download our HIV mobile apps:Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=US Apple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691 

Anne Brisson is a creativity educator, professional artist, and researcher based in Montreal, Canada. She brings more than 25 years of experience in business, design, and adult education. Anne holds an MS in the Science of Creativity from the Center for Applied Imagination, a Bachelor's in Adult Education, and a Bachelor's in Landscape Architecture and Urban Design. She is now a PhD candidate at Concordia University, where she researches how drawing and mark-making develop affective creativity skills in adult learners.In this episode of the Creative Flow podcast, Anne explains how art thinking differs from design thinking. Design thinking improves solutions to a known problem, while art thinking asks whether we are solving the right problem. She describes leading early patient partnerships in Canada's pharmaceutical industry. When an HIV patient group first threatened to sue, she chose to listen with empathy. Ten months later, the group honored her with an award on World AIDS Day. Anne links that success to three affective creative skills: openness to novelty, tolerance for complexity, and tolerance for ambiguity. She argues that these skills drive our cognitive thinking, and that a daily drawing practice, with nothing more than a pen and paper, builds the courage to turn ideas into action.To see the artwork described in this podcast, visit her Instagram account at @parlamainestudio.This conversation shows how the arts strengthen the courage to create. Anne offers a fresh voice to the Science of Creativity. She reminds us that bold ideas matter only when we find the courage to act on them, at any age. If you have studied at the Center for Applied Imagination, attended CPSI, or practice deliberate creativity, this episode will challenge how you approach the problems you choose to solve. Follow Creative Flow and listen now.

Netflix kijkt niet lekker weg op de beurs. Het aandeel is dit jaar al bijna een kwart gedaald. Werk aan de winkel dus voor de baas Ted Sarandos. Die nu ook openlijk toegeeft (bij de vrienden van persbureau Bloomberg) dat zijn bedrijf te langzaam groeit. De tijd dat klanten op het platform blijven hangen is te laag, geeft hij eerlijk toe. Er moet daarom wat veranderen. Vraag is alleen of Netflix het op eigen kracht gaat redden. Een grote overname is van de baan, de miljardenuitgaven brengen nog niet extra abonnees en live-events werken ook nog niet echt. Deze aflevering helpen we de ceo een eindje op weg. Met behulp van mediadeskundige Kirsten Jan van Nieuwenhuizen van de podcast Content Wars. We kijken wat 'ie moet doen om de boel op de rit te krijgen. Hebben we het ook over Nokia. Dat kennen de Millenials onder jullie nog als telefoonmaker. Tegenwoordig zijn de Finnen een defensiebedrijf. Een serieus beursbedrijf ook. Verder hoor je over Grindr (dat een zorgbedrijf koopt), over Jerome Powell die ontslagen moet worden (vindt Trump) en we bespreken uitgebreid de cijfers van Micron. De winst is verelfvoudigd, maar toch zijn er zorgen onder beleggers. Te gast: Jean Paul van Oudheusden van Markets Are Everywhere BNR Beurs is een journalistiek onafhankelijke productie, mede mogelijk gemaakt door Saxo. Over de makers: Jelle Maasbach is presentator van BNR Beurs en freelance financieel journalist. Zijn favoriete aandeel om over te praten is Disney, maar daar lijkt hij de enige in te zijn. Sinds de eerste uitzending van BNR Beurs is 'ie er bij. Maxim van Mil is presentator van BNR Beurs en journalist bij BNR, waar hij zich focust op de financiële markten en ontwikkelingen in de tech-wereld. Je krijgt hem het meest enthousiast als hij kan praten over ASML, of oer-Hollandse bedrijven zoals Ahold of ABN Amro. Jorik Simonides is presentator van BNR Beurs, economieredacteur en verslaggever bij BNR. Hij wordt er vooral blij van als het een keer níet over AI gaat. Je hoort hem ook in de BNR-podcast Moerdijk: dorp van de rekening. Milou Brand is presentator van BNR Beurs, freelance podcastmaker en columnist bij het Financieele Dagblad. Jochem Visser is presentator van BNR Beurs, maakt Beursnerd XL en is redacteur bij de podcast Onder Curatoren. Vraag hem naar obscure zaken op financiële markten en hij vertelt je waarom het eigenlijk nóg leuker is dan je al dacht. Donner Bakker is presentator van BNR Beurs en economieredacteur bij BNR. Hij volgt macro-economische ontwikkelingen met bovengemiddelde interesse, net als de beursgenoteerde datingapps. Je hoort hem ook in de BNR-podcast All In The Game. Over de podcast: Met BNR Beurs ga je altijd voorbereid de nieuwe beursdag in. We praten je in een kleine 25 minuten bij over alle laatste ontwikkelingen op de handelsvloer. We blijven niet alleen bij de AEX of Wall Street, maar vertellen je ook waar nog meer kansen liggen. En we houden het niet bij de cijfers, maar zoeken ook iedere dag voor je naar duiding van scherpe gasten en experts. Of je nu een ervaren belegger bent of net begint met je eerste stappen op de beurs, de podcast biedt waardevolle inzichten voor je beleggingsstrategie. Door de focus op zowel de korte termijn als de lange termijn, helpt BNR Beurs luisteraars om de ruis van de markt te scheiden van de essentie.See omnystudio.com/listener for privacy information.

This week, we feature new research on statin therapy in older adults, treatments for IgG4-related disease and advanced breast cancer, and a once-weekly oral regimen for HIV. We review Andes virus and follow a challenging case of a disseminated infection. Articles explore scientific independence, opioid-settlement funds, pharmaceutical policy, and the role of community in patient care.

Only about 13 people in the world are considered cured of HIV. The youngest is a patient at The University of Kansas Cancer Center whose treatment for leukemia also cleared HIV from his body. The doctors who treated him explain how it happened and why his case is getting international attention.

Conspiracy theories aren't a sign of poor judgement or personality flaws. Constructed from a shared language, they actually offer a means for someone to try and make sense of an uncertain or stressful event.That's according to Henrich Greve, Professor of Entrepreneurship at INSEAD, speaking on this episode about his new book, co-authored with Stanford University's Huggy Rao: Ctrl+Alt+Doubt: Decoding the Language of Online Conspiracy Talk.Greve explains why anyone can end up believing in conspiracy theories, how "gateway" theories work like gateway drugs, why the calmest, most rational-sounding posts spread the furthest, and why people often hold several contradictory theories at once as a kind of psychological safety net.The conversation also covers real-world harms, from vaccine hesitancy and the return of measles to South Africa's HIV denialism and the January 6th Capitol attack, before turning to what actually works, and what doesn't, in slowing the spread of harmful conspiracies.Chapters00:00 Introduction: why conspiracy theories spread faster than ever02:03 Why the book was written, and what past research got wrong06:36 Defining a conspiracy theory, and how widespread they are11:23 Reframing believers as problem solvers, not "dupes"15:00 How the conspiracy "toolkit" is learned and spreads 21:03 The language of conspiracy talk: calm words, hashtags and community24:23 Why people believe multiple, even contradictory, theories26:56 Real-world harms: vaccines, violence and the return of measles30:28 Conspiracy theories at state level: South Africa, Russia, January 6th34:04 What actually works, and doesn't, in limiting the spread40:34 Closing thoughts and where to find the bookRead the related INSEAD Knowledge article.

More than half of people living with HIV in the U.S. are over the age of 50, and within a few years it will likely be more than two thirds, if we're not there already. You probably already know first-hand the challenges of adapting and evolving care to meet the needs of a patient population that is older than we envisioned back when we formed a lot of the HIV care systems we now rely on.   This month, Meredith Greene, M.D., joins us to talk about that adaptation and evolution by discussing her path to becoming a leading HIV specialist and geriatrician, her experience creating the distinguished Golden Compass clinic in San Francisco, and her efforts to apply that knowledge and experience in her current role as an associate professor of medicine at the Indiana University School of Medicine and a scientist at the Center for Aging Research.   Support the podcast by visiting the transcript, which includes a summary of key points and additional resource links: https://www.thebodypro.com/podcast/hiv/future-hiv-care-meredith-greene-aging-geriatric-clinic-sept-2026   The host and executive producer of this podcast is Myles Helfand; our senior production manager is Alina Mogollon-Volk; our senior producer is Lizzie Warren; and our audio editor is Kim Buikema. Thanks this month to our contributing editor Roger Pebody for his background research and interview prep assistance.

Ebola outbreaks occur in areas where many people are living with HIV; however, there is very little evidence on how people with HIV respond to Ebola vaccines. In this edition of the podcast, we talk to authors of a study assessing the safety and immunogenicity of an Ebola vaccine in people with well controlled HIV. Click here to read the full article: https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00118-9/fulltext

The story of HIV prevention has changed dramatically over the past four decades. What was once dominated by fear and limited options has become a field shaped by scientific breakthroughs, greater understanding, and a growing appreciation of personal choice. Yet while medicine has transformed the ways people can protect themselves, one element remains as important as ever. Prevention depends on communication. Every intimate encounter involves two people, each bringing their own experiences, expectations, and preferences. Reaching a shared understanding is rarely as simple as it appears.

This story is one of the most powerful testimonies you'll ever hear. On today's edition of Family Talk, Roger Marsh welcomes author, ordained minister, and Bible professor Dr. Christopher Yuan, who shares his journey from drug dealing, prison, and an HIV diagnosis to radical transformation in Jesus Christ. To support this ministry financially, visit: https://www.oneplace.com/donate/707/29?v=20251111

Join Professor Regina Callion, MSN, RN, as she reviews isolation precautions—an essential NCLEX topic that can protect patients and healthcare workers. Test your knowledge with a “Stop the Spread” quiz covering contact, airborne, droplet, and standard precautions for C. difficile, pulmonary tuberculosis, influenza, pertussis, HIV, rubella, and more. You'll identify the correct precaution and recognize whether your challenge is knowledge, application, or priority. Master infection-control questions before test day so you can answer with confidence. Grade yourself, review your missed topics, and continue your NCLEX preparation at https://www.ReMarNurse.com.  

Bring the tissues for this one. ❤️ We sit down with the incredible people behind the now Emmy-winning short documentary “The Last Gift: Jim's Courage, Our Hope”—a beautiful, heartbreaking, and deeply inspiring story about one man's extraordinary final gift to HIV research. (The Last Gift Study⁠) We talk about Jim's legacy, the remarkable strides being made in HIV/AIDS treatment and cure research, and the humanity behind the science. And THEN…director Ryan Neisz actually let us hold the Emmy!

Your innate immune system handles 99% of threats without you noticing. But when it's not enough, your body builds a custom-made response, one specific enough to remember an exact enemy for years.In this episode of the Jack Westin MCAT Podcast, Mike and Molly continue their immunology series with the adaptive immune system: the slower, highly specific branch of immunity that brings memory, precision, and long-term protection. Building on the last episode's innate immunity foundation, this episode walks through exactly how B cells and T cells get activated, how the body finds the right defense out of millions of possibilities, and why HIV is so devastating to this entire system.Get started with our resources!

In a live episode of the Theory of Change podcast, Buddy Shah, CEO of the Clinton Health Access Initiative and chair of the Anthropic Long Term Benefit Trust, shared an inside look at the intersection of global health, market-shaping agreements, and artificial intelligence. "The mistake that many of us are making ... is looking for an AI point solution. What's a cool use case where you can develop an AI tool and slot it into an existing system? And I think the much more important question is: If you could redesign the system for a world where you have very powerful AI tools, what would that look like?" Shah said during the podcast, which was recorded last week at the Devex Impact House in New York on the sidelines of the United Nations General Assembly. Shah pulled back the curtain on CHAI's landmark deal to secure generic manufacturing of lenacapavir — a twice-yearly injectable drug offering 99% effectiveness against HIV infection. By negotiating the price down from $28,000 per year in the U.S. to $40 per patient per year in lower-income countries, Shah explained how CHAI, Gilead, generic manufacturers, and global health partners believe they are creating a path that could spell the end of HIV over the next decade. Addressing his dual role managing corporate governance at Anthropic, Shah previewed how artificial intelligence could fundamentally reshape health delivery in low- and middle-income countries through mobile diagnostics and AI clinical assistants. He emphasized that LMICs may leapfrog high-income nations in adopting these technologies, while highlighting how incoming philanthropic capital from the AI sector could help fund major systemic solutions.

In this podcast my guests Sherry Jackson Thompson, Director; Wylie Caudill, Steve; and Kyle Wade, numerous roles - all female - discuss the upcoming production of Jeffrey by Act Out Theatre, exploring its themes of love, humor, and the impact of the AIDS crisis. They share insights into the mission of Act Out Theatre, the character dynamics within the play, and the challenges of rehearsing without a dedicated space. The discussion highlights the relevance of the play in today's context, emphasizing the importance of community and inclusivity in theatre.Jeffrey was written in the shadow of a profound public health and social crisis. Opening off-Broadway to much success in 1992, the play emerged during the AIDS epidemic, when fear, stigma, misinformation, and political inaction shaped the lives of countless Americans. Although the circumstances are different, the parallels between then and now are disturbingly similar.The early 1990s in America were marked by deep social and political divisions. Many people living with HIV and AIDS faced discrimination, isolation, and the loss of friends and loved ones while public institutions struggled to respond with the urgency the crisis demanded. The Reagan administration had been widely criticized for its delayed and inadequate public response during the early years of the epidemic, a failure that intensified the pain experienced by affected communities. These circumstances helped fuel activism and demanded that the public confront the human cost of silence.Today, as we recognize disturbing parallels between now and then – we honor humor and heart as a means to a kinder day. Sadly, communities still confront social injustice, political polarization, and marginalization today. For more and to connect with us, visit https://www.artsconnectlex.org/art-throb-podcast.html

This week, PhD student Bright Ofori talks about his research on HIV stigma and mental health among older adults living with HIV. With advances in treatment, people living with HIV are living longer. However, this raises new questions about what aging with HIV looks like; what happens when the social impacts of HIV (including stigma, shame, and fear of disclosure) last after diagnosis? Bright's research compares the experiences of older adults living with HIV across two different settings: the Ashanti Region of Ghana and African, Caribbean, and Black communities in Ontario. How do culture, community, and social support shape experiences of HIV stigma? How can stigma affect mental health, including experiences of depression and anxiety? And how can researchers capture these experiences while ensuring that the people and communities affected have a meaningful role in building a stronger voice for affected individuals? Join Kuljeet Chohan and Victor Lau as they hear more about Bright's methodologies and tackling how stigma exists, to understand a little more about the prevalence of HIV stigma and persisting through with mental health challenges. LinkedIn: https://www.linkedin.com/in/bright-ofori-phd Instagram: @i.am.bryt  ---------------------------------------- Recorded on Tuesday, September 22, 2026 Produced by Kuljeet Chohan Theme tune “Feelin Good” provided by FreeBeats.io (Produced by WhiteHot)

I'm Antonio Saillant, a filmmaker, producer, and storyteller. I've spent years helping others share their stories. Now I'm stepping forward with mine.Losing my sister to HIV, losing my parents to Alzheimer's, and supporting loved ones with intellectual disabilities taught me the importance of compassion, caregiving, and making people feel heard.Learning about the Ryan Seacrest Foundation's work bringing creativity and broadcasting to children in pediatric hospitals gave me another heartfelt reason to enter this competition.⭐ VOTING BEGINS OCTOBER 5!Visit the link in my bio or description to see my Top Host profile. Share this with someone who believes in the power of storytelling.https://tophost.org/2026/antonio-saillantEvery voice matters. Thank you for supporting mine.Subscribe to my YouTube Channel Here.

About this episode:   Life expectancies for those living with HIV are nearly identical to those living without the virus, thanks to groundbreaking advancements in medicine and care. But that data point doesn't tell the full story about the unique needs and nuanced challenges facing those with HIV, particularly as that population skews increasingly older. In this episode: Keri Althoff and Vanessa Johnson, co-authors of a new report on aging and HIV, explain why and how prevention and treatment should adapt to support lifelong health. Guest:  Keri N. Althoff, PhD, MPH, is a professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health. Vanessa Johnson, MPA, JD, is a recognized advocate, community leader, and champion for people living with HIV. She is the co-executive director at Ribbon, a social justice organization, and senior advisor to ROC4Aging+, a project that seeks to improve quality of life for those aging with HIV. Host:  Stephanie Desmon, MA, is a former journalist, author, and the director of public relations and communications for the Johns Hopkins Center for Communication Programs. Show links and related content:  The Lancet HIV Commission on ageing and HIV: a global perspective—The Lancet HIV Commissions Amy Justice and Keri Althoff on the Lancet HIV Commission on ageing and HIV—The Lancet On the Cusp of Eliminating HIV—Hopkins Bloomberg Public Health Magazine Growing and Aging: The Population of People Living with HIV—Johns Hopkins Bloomberg School of Public Health "On Going Backwards": A New HIV/AIDS Epidemic?—Public Health On Call (May 2024) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. You can also email PublicHealthQuestion@jhu.edu to request a transcript. AI disclosure (as of September 2026): The conversations you hear on the podcast are happening between real humans, and real humans are developing and researching episodes behind the scenes. In addition to real human audio engineers, Public Health On Call uses AI production tools to assist with the removal of filler words and improve audio quality. If you have any questions about our use of AI, please reach out to PublicHealthQuestion@jhu.edu.  Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌PublicHealthPod on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

☎️ This week I'm hung up on past guest Dr. Shanea Thomas and the Nolan Wells cell phone forensic report that Ben Crump just released. What happens when gaming, HIV advocacy, queer youth, and community collide? This week on the Hung Up Podcast, we're getting into the REAL work behind creating safer, more connected spaces for LGBTQ+ people. Rosko shares his HIV advocacy work journey, we celebrate one year on the Philly Black Pride Board, and unpack his connection to the growing Queer gamer community. It's a conversation about visibility and what it really means to show up for your people. instagram.com/roskos.modernlife Bloomsbury: https://www.bloomsbury.com/us/accountable-care-and-identity-camaraderie-for-transgender-and-queer-service-providers-9781666961423/

  Most people don't think about home accessibility until mobility changes force the conversation. But what if you decide to take control of the unknown and design your living space for whatever the future might bring? My guest, Sarah Timmerman, explains how she took total control of her future by designing and building what she calls The House That MS Built—a home engineered from the foundation up to future-proof her independence through smart, universal design and relentless self-advocacy.  We'll also tell you about a research team that identified 4 biomarkers that, together, can help a neurologist understand whether a stem cell therapy is working for their patient weeks before that patient returns to the clinic. We're sharing results of a trial that answered the question, "Can diet actually change what's happening at the cellular level inside the brain?" You'll want to hear these results! And we'll tell you about a research team that has developed a derivative of an HIV medication that restored mobility and vision to mice with the mouse version of MS.  We have a lot to talk about! Are you ready for RealTalk MS??! This Week:  The House that MS Built  :22 Have you downloaded the new RealTalk MS app for your iOS or Android device?   1:16 Researchers at Tisch Multiple Sclerosis Research Center of New York identify 4 biomarkers that can help physicians track the response to stem cell therapy in people living with progressive MS   2:01 New research identifies how gut health can lead to nerve cell damage in MS   4:49 Repurposed HIV medication restores lost function in the mouse model of MS  8:48 Sarah Timmerman shares her story and explains how relentless self-advocacy became the foundation for the House that MS Built  12:55 Share this episode  24:09 Next week  24:29 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/474 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes at www.RealTalkMS.com DOWNLOAD: The RealTalk MS App iOS: https://apps.apple.com/us/app/realtalk-ms/id6769516594 Android: https://play.google.com/store/apps/details?id=com.realtalkms.app&pcampaignid=web_share REGISTER: ECTRIMS Patient Community Day 2026 https://ectrimspatientcommunity.eu STUDY: Effect of Intrathecal Injection of Mesenchymal Stem Cell-Neural Progenitors on Cerebrospinal Fluid Biomarkers in Progressive Multiple Sclerosis https://pmc.ncbi.nlm.nih.gov/articles/PMC13585449 STUDY: High-Fat Diet Promotes T-Cell Mediated Synaptic Dysfunction in Multiple Sclerosis https://link.springer.com/article/10.1186/s12974-026-04049-x STUDY: The Nucleoside Analog Kamuvudine-9 Shows Protective and Therapeutic Efficacy in a Mouse Model of Multiple Sclerosis https://science.org/doi/10.1126/scitranslmed.aei2870 JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on X, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 474 Guest: Sarah Timmerman Privacy Policy

Zafar Mirza is a Pakistani public health professional who served as the special assistant to the prime minister Imran Khan for Health from 2019 to 2020.The Pakistan Experience is an independently produced podcast looking to tell stories about Pakistan through conversations. Please consider supporting us on Patreon:https://www.patreon.com/thepakistanexperienceTo support the channel:Jazzcash/Easypaisa - 0325 -2982912Patreon.com/thepakistanexperienceAnd Please stay in touch:https://twitter.com/ThePakistanExp1https://www.facebook.com/thepakistanexperiencehttps://instagram.com/thepakistanexpeperienceThe podcast is hosted by comedian and writer, Shehzad Ghias Shaikh. Shehzad is a Fulbright scholar with a Masters in Theatre from Brooklyn College. He is also one of the foremost Stand-up comedians in Pakistan and frequently writes for numerous publications. Instagram.com/shehzadghiasshaikhFacebook.com/Shehzadghias/Twitter.com/shehzad89Join this channel to get access to perks:https://www.youtube.com/channel/UC44l9XMwecN5nSgIF2Dvivg/joinChapters:0:00 Introduction1:00 What happened at PIMS?4:20 Why it happened12:15 Neonatal Mortality in Pakistan18:06 Hepatitis C, Diabetes, HIV and Stunted Growth29:59 Healthcare System has collapsed37:30 Primary Health care and priorities of the Government49:00 Solutions and why Governments keep failing

Welcome back to our Interview series! This week on Queer News, Anna DeShawn continues to bring you the stories that matter most to our community! Anna has a couple Queer News headlines to share, then later, join Anna for an exclusive interview with advocate, and chair of the council of justice leaders with the Elizabeth Taylor AIDS Foundation, Robert Suttle! Robert's work is rooted in combating the criminalization of HIV through consultations, and education on the stigmas and harmful legislation surrounding HIV. His passion has personal ties, as he himself experienced felony charges and jail time as a result of the existing laws related to HIV.  Through The Sero Project, a program Robert co-founded, he  uplifts voices directly impacted by HIV criminalization and strongly advocates for policy reform across the globe.  On this episode of Queer News, Anna and Robert discuss the criminalization of HIV, Robert's personal story, states with laws actively criminalizing HIV, and ways people can support the HIV is not a crime movement and the true not crime series. You can find Robert Suttle on instagram @suttlevision.  Want to support this podcast?

We're now several years, thankfully, past the COVID-19 pandemic, but as even a casual glance at daily news headlines reminds us, the challenge posed by infectious diseases is not going anywhere anytime soon. And with the arrival of fall weather and the holiday gatherings that will soon be right around the corner, it's an excellent time to check in with one of the world's pre-eminent infectious disease experts — Dr. David Wohl. Dr. Wohl is a Professor of Medicine in the Division of Infectious Diseases at UNC, and he's spent over 20 years leading research into the prevention and treatment of HIV. In 2020, he helped lead the UNC clinical and research response to COVID-19. And this past week, Dr. Wohl was kind enough to make some time to chat with NC Newsline about how North Carolinians can best protect themselves and their families from any number of dangerous infectious diseases. Click here to listen to the full interview with Dr. David Wohl , Professor of Medicine in the Division of Infectious Diseases at UNC.

Are you ready to rethink initial HIV treatment with recent trial data? Credit available for this activity expires: 9/25/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/power-two-redefining-hiv-management-2dr-treatment-patients-2026a1000z4a?ecd=bdc_podcast_libsyn_mscpedu

Medication that helps prevent HIV transmission is readily available in Australia, including for temporary visa holders and those without Medicare. So why are some LGBTQI+ migrants missing out? - دارویی که به پیشگیری از انتقال اچ‌آی‌وی کمک می‌کند، در استرالیا به‌راحتی در دسترس است؛ حتی برای دارندگان ویزاهای موقت و افرادی که تحت پوشش مدیکر نیستند. پس چرا برخی از مهاجران LGBTQI+ از این خدمات محروم می‌مانند؟#sbsaudiopodcast - #sbsaudiopodcast

INTRODUCTION:Fever of Unknown Origin, or FUO: We have all had a fever at some point—maybe from seasonal flu or a brief stomach bug—where the body turns up the heat, fights off the bug, and recovers in a couple of days. Fever is a very efficient defense mechanism to fight microorganisms by making your body a hostile environment where they cannot survive. But what happens when a fever lasts for weeks, standard tests come back normal, and usual fever reducing medications do not seem to work?We will talk about the surprising root causes, the latest imaging technology like PET scans, and what to do when a fever refuses to break. Whether you are a medical student, a healthcare professional, or simply curious about how our body's defense mechanisms work, this episode is for you. Let us get into it!Definition of Fever of Unknown Origin.A standard fever is like a smoke alarm going off when you burn toast—you quickly spot the cause, fix it, and the alarm stops. FUO is like an alarm ringing continuously for weeks, but despite searching every room, you cannot find the source of the fire.Clinical Criteria (Classic FUO):1. Temperature >38.3 C measured on multiple occasions.2. Duration of at least 3 weeks.3.Unexplained after 1 week of intensive outpatient or inpatient evaluation (or three outpatient visits).Categories of FUO.1. Classic FUO: The traditional presentation described above.2. Nosocomial (Hospital-Acquired) FUO: Fevers in hospitalized patients without infection upon admission.3. Neutropenic FUO: Fevers in immunocompromised patients (e.g., undergoing chemotherapy) with low white blood cell counts.4. HIV-Associated FUO: Fevers lasting weeks in patients with HIV, often driven by opportunistic infections like Tuberculosis or CMV, that stands for cytomegalovirus. What a mouthful!The Big Four Causes are:Infections (~30–40%): Atypical presentations of common diseases (e.g., hidden abscesses, endocarditis, tuberculosis, or tick-borne illnesses). Our priority will be to determine if this patient is having an infection, unless we get clinical manifestations that would guide us in another direction.Autoimmune & Inflammatory Diseases (~20–30%): The immune system overreacting and attacking the body's tissues (e.g., Adult-onset Still's disease, Temporal Arteritis/Giant Cell Arteritis, Lupus).Malignancies / Cancers (~10–20%): Blood cancers (Lymphoma, Leukemia) or solid tumors (Renal cell carcinoma). Infections, autoimmune/inflammatory diseases, and malignancies cover 60-90% of the causes of FUO.Miscellaneous / Drug Fevers (~10–15%): "Drug fever" caused by adverse reactions to common medications (e.g., antibiotics, anti-seizure meds), thyroid storm, or deep vein thrombosis (DVT).Modern Medicine: Advanced imaging (CT, MRI, PET scans) which have helped us diagnose cancers and abscesses much earlier. As a result, modern FUOs are increasingly driven by autoimmune conditions, non-infectious inflammatory disorders. Sometimes it feels like we solve one problem and uncover another one!Important: Some cases remain undiagnosed (up to 30–50%) and resolve without a specific label.Diagnostic Approach:Step 1: The "Detective Work" (History & Physical):● Detailed History: Travel history, animal exposure (ticks, pets), occupational hazards, social history, medication review (to exclude drug fevers), and family history.● Potential Diagnostic Clues: Looking for subtle signals (e.g., a new heart murmur, temporal tenderness, hidden skin rashes, or swollen lymph nodes).Step 2: Basic Tiered Testing:● Blood Work: CBC (complete blood count), inflammatory markers (ESR, CRP, Ferritin), comprehensive metabolic panel, blood cultures.● Targeted Serologies: HIV, viral panels, autoimmune antibodies (ANA, Rheumatoid Factor).● Initial Imaging: Chest X-ray, abdominal ultrasound.Step 3: Advanced Diagnostic Workup:FDG-PET/CT Imaging: One of the most significant updates in recent guidelines. FDG-PET/CT uses a radioactive sugar tracer to highlight areas of high metabolic activity (inflammation, infection, tumor) throughout the entire body in a single scan. FDG-PET is a functional nuclear-imaging technique that uses ¹⁸F-fluoro-deoxy-glucose (FDG) — a radioactive glucose analog — to map tissue glucose metabolism.Targeted Biopsies: Biopsying tissues guided by PET scan findings (e.g., lymph node, liver, or temporal artery)."Refractory" Fevers:Fever vs. Hyperthermia: Standard fevers are driven by the brain's hypothalamus resetting the body's thermostat upward (often mediated by prostaglandins). ● Antipyretics (acetaminophen, NSAIDs) block prostaglandin synthesis.● If a fever does not respond to antipyretics, it may indicate non-prostaglandin-mediated inflammation (e.g., severe cytokine storm, drug-induced hyperthermia, or central nervous system dysregulation).Empiric Treatment vs. Observation:● The "Hold Your Horses" Principle: Current guidelines strongly advise against starting empirical antibiotics or steroids right away in stable patients. Antibiotics can mask infections and produce false-negative culture results, while steroids can hide inflammatory signs or exacerbate hidden infections.● When to Treat Empirically: Reserved for hemodynamically unstable patients, neutropenic patients, or specific high-suspicion conditions (e.g., suspected Temporal Arteritis to prevent blindness).Diagnostic Trial: Naproxen Test (Historical & Clinical Pearl): A brief trial of naproxen can sometimes distinguish tumor fevers (which often drop sharply in response to NSAIDs) from infectious fevers, though it is used cautiously as a supportive diagnostic clue rather than a rule. So, if a patient responds to a trial of naproxen, then we can suspect a tumor as a cause of the patient's fevers. But it is not a strong recommendation.A 2019 systematic review/meta-analysis (15 studies, 582 patients) found a 94.1% success rate for naproxen in treating confirmed neoplastic fever. The test is not specific and lacks validation, but I can see the importance of knowing this: Naproxen is effective against cancer fever.FUO evaluation is a marathon, not a sprint. Re-evaluating the patient daily in the hospital for new physical clues is often more valuable than ordering endless specialized tests. I would like to emphasize that modern tools PET/CT have transformed how quickly we locate hidden inflammation. Also, let us remember that a huge proportion of undiagnosed FUOs eventually resolve spontaneously with good long-term outcomes, provided serious conditions have been systematically ruled out.Take away messages:First, FUO is a diagnostic marathon, not a sprint. Finding the cause takes patient detective work, careful daily exams, and targeted testing rather than rushing into quick fixes.Second, modern imaging like FDG-PET scans has completely transformed how we spot hidden inflammation and infection long before standard blood work gives us an answer.And finally, 'refractory' fevers require caution. If a fever is not responding to standard antipyretics, starting antibiotics or steroids right away can hide the real culprit. In stable patients, holding off and continuing the search is often the safest path.__________________Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week!References:1) David AB, Quinlan JD. Fever of Unknown Origin in Adults. American Family Physician. 2022;105(2):137-143.2) Wright WF, Stelmash L, Betrains A, Mulders-Manders CM, Rovers CP, Vanderschueren S, Auwaerter PG; International Fever and Inflammation of Unknown Origin Research Working Group. Recommendations for Updating Fever and Inflammation of Unknown Origin From a Modified Delphi Consensus Panel. Open Forum Infectious Diseases. 2024;11(7):ofae298.3) Wright WF, Durso SC, Forry C, Rovers CP. Fever of unknown origin. BMJ. 2025;388:e080847.4) Wright WF, Auwaerter PG. Fever and fever of unknown origin: review, recent advances, and lingering dogma. Open Forum Infectious Diseases. 2020;7(5):ofaa132.5) Cunha BA, Lortholary O, Cunha CB. Fever of unknown origin: a clinical approach. The American Journal of Medicine. 2015;128(10):1138.e1-1138.e15.6) Nazar AH, Naswa N, Sharma P, et al. Spectrum of 18F-FDG PET/CT findings in patients presenting with fever of unknown origin. American Journal of Roentgenology. 2012;199(1):175-1851) Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/. Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week!

A stark advert picturing a gravestone chiselled with ‘AIDS: DON'T DIE OF IGNORANCE' captured the horror of this disease in the 1980s. Now, for HIV-infected people able to access anti-retroviral therapies, life expectancy is normal.How were these amazing medicines developed and how have they transformed lives? Why is it so difficult to eradicate HIV or to develop a vaccine to prevent infection? What does the future hold in the quest to stop the global scourge of AIDS?This lecture was recorded by Matt Higgins  on the 16th of September 2026Matt studied natural sciences at Christ's College in the University of Cambridge and a Ph.D. in structural biology at the Laboratory of Molecular Biology. He started his research group with a Royal Society University Research Fellowship in 2005 and moved to the University of Oxford in 2010. He is currently the E. P. Abraham Professor of Structural Biology and a Professorial Fellow at Merton College, Oxford. He is a Fellow of the Academy of Medical Sciences and a member of the European Molecular Biology Organisation.The transcript of the lecture is available from the Gresham College website: https://www.gresham.ac.uk/watch-now/hiv-pandemicGresham College has offered free public lectures for over 400 years, thanks to the generosity of our supporters. There are currently over 2,500 lectures free to access. We believe that everyone should have the opportunity to learn from some of the greatest minds. To support Gresham College's mission, please consider making a donation: https://www.gresham.ac.uk/get-involved/support-us/make-donation/donate-today Website:  https://gresham.ac.ukX: https://x.com/GreshamCollegeFacebook: https://facebook.com/greshamcollegeInstagram: https://instagram.com/greshamcollegeBluesky: https://bsky.app/profile/greshamcollege.bsky.social TikTok: https://www.tiktok.com/@greshamcollegeSupport Us: https://www.gresham.ac.uk/get-involved/support-us/make-donation/donate-todaySupport the show

05:13 Patrick Clancy's 60 Minutes Interview & Lindsay Clancy16:47 Nolan Wells: Mississippi Grand Jury Declines to Indict32:34 The "Butcher of Tompkins Square Park" & Sunny Hostin's Jury Story40:42 Waco Mailbag: AI, HIV & Helping Neighbors46:54 Cornell Gang-R4pe Allegations: What Happened?52:55 The Cornell Lawsuit & Jane Doe's Allegations01:13:34 Cornell University Police & The Initial Investigation01:25:45 Cornell's Response to the Alleged Gang R4pe01:35:26 The Cornell Daily Sun: "Cornell Won't. We Will."01:50:52 R4pe Allegations Against Clavicular02:08:14 The "Perfect Victim" Myth & Online Reactions02:13:22 Cuties Corner: San Diego Animal Shelter Crisis02:14:50 The Trump Administration & Endangered Species Protections02:18:49 Trump, the White House & the Fight Over Press Access02:34:41 The DOJ Lawyer Who Wrote About Hitler02:41:06 Gaza, Genocide Claims & the International Court of Justice02:48:13 DOJ Challenges State Restrictions on Handg*n Sales to Under-21s02:51:44 Trump & Zohran Mamdani Meet Again02:55:15 Surrogacy, Ab0rtion & the Supreme Court Baby-Custody FightThis week on Without a Country, Corinne Fisher begins by discussing her reaction to Patrick Clancy's 60 Minutes interview before turning to the latest developments in the death of 18-year-old Nolan Wells, including a Mississippi grand jury's decision not to indict. The show then takes a deep dive into the lawsuit alleging that a Cornell University student was drugged and gang r4ped by fraternity members, examining the allegations, Cornell's response, the university's Title IX process, and the extraordinary reporting by the student-run Cornell Daily Sun. Corinne also discusses rape allegations against social-media influencer Clavicular. From there, it's time for a Cuties Corner focused on the Trump administration's changes to endangered species protections. The episode then turns to the White House's restrictions on media access, the fight over press freedom, a DOJ lawyer's past writing about Hitler, and historical parallels involving propaganda and control of the press. Corinne also covers the ongoing genocide in Gaza and international calls for accountability, a federal dispute over handgun sales to adults under 21, and the latest meeting between Donald Trump and Zohran Mamdani. The episode ends with a conversation about surrogacy after the Supreme Court's involvement in a case involving a surrogate who refused to terminate a pregnancy after a serious fetal diagnosis. LOS ANGELES! We SOLD OUT the Belly Room for Oct 25 so we moved to the MAIN ROOM! GET TICKETS HERE: https://events.leapevents.com/event/gash-2026NEW YORK CITY! GWF Presents Sl*utsgiving 2.0 at GRAMERCY THEATRE on Nov 17GET TICKETS HERE: https://www.ticketmaster.com/event/0000651B910F9D34SUBSCRIBE TO THE PATREON:https://patreon.com/WithoutACountry?utm_medium=unknown&utm_source=join_link&utm_campaign=creatorshare_creator&utm_content=copyLinkFOLLOW WITHOUT A COUNTRY ON IG: https://www.instagram.com/withoutacountrypodcast/FOLLOW CORINNE ON IG: https://www.instagram.com/philanthropygalFOLLOW MIKE ON IG: https://www.instagram.com/themharrington/FOLLOW ALONG:ENEMY OF THE STATE: Mississippi Grand Jury in Nolan Wells Decision https://www.npr.org/2026/09/22/nx-s1-5977673/questions-remain-after-grand-jury-declines-indictment-in-nolan-wells-deathMAIN STORIESCornell Gang R4peCORNELL DAILY SUN REPORTING9/18https://www.cornellsun.com/article/2026/09/tccsuykuvb4z?utm_source=chatgpt.com9/21 earlyhttps://www.cornellsun.com/article/2026/09/university-releases-statement-on-alleged-gang-rape-at-chi-phi?utm_source=chatgpt.com9/21 later https://www.cornellsun.com/article/2026/09/editorial-cornell-won-t-we-willFrom NY Post (more graphic)https://nypost.com/2026/09/18/us-news/cornell-frat-bros-gang-rape-student-texting-free-p-y-during-sick-assault-shocking-lawsuit/CLAVICULAR v ALORAH ZIVAhttps://www.npr.org/2026/09/22/nx-s1-5978033/braden-peters-clavicular-looksmaxxing-rape-accusation&https://nypost.com/2026/09/22/us-news/clavicular-rape-charge-includes-grim-claims-about-luring-teen-to-familys-3m-cape-cod-mansion-before-exploiting-her-months-later/VIDEO CLAVICULAR POSTED IN RESPONSE: https://www.instagram.com/reel/Ddm2mrwvAl5/CUTIES CORNEREndangered Specieshttps://www.reuters.com/legal/litigation/timeline-trump-administration-moves-weaken-endangered-species-protections-2026-09-21/GUUUURLTrump Blocking Mediahttps://thehill.com/homenews/administration/6105819-doj-trump-administration-defense-white-house-media-ban/Lawsuit written up by Michael VelchikMichael Velchik is an American lawyer, currently serving as senior counsel at the US Department of Justice.https://archive.is/jXhDsVatican Gaza Protesthttps://apnews.com/article/italy-gaza-genocide-vatican-pope-a704633f835d88c49f4c733f640c52c7Firearms for Teenshttps://www.firearmsnews.com/editorial/18-20year-old-handgun-ban-unconstitutional/560111Surrogacy Legal Battle https://www.nytimes.com/2026/09/22/us/politics/supreme-court-surrogate-abortion-custody.htmlSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What's actually flowing through the “natural gas” pipes connected to your home—and did we get something wrong in our air-conditioning series? Which careers can an organic chemistry student pursue, how do topical pain-relief gels work, and what could make a successful HIV medication suddenly stop working? Melissa and Jam answer listener questions, revisit past episodes, correct the record, and stumble into a genuinely fascinating pharmaceutical mystery. Plus, could more chemistry history and chemistry-education stories be coming to the podcast? Support this podcast on Patreon Buy Podcast Merch and Apparel Check out our website at chemforyourlife.com Watch our episodes on YouTube Find us on Instagram, Twitter, and Facebook @ChemForYourLife Timestamps 00:00 — Another round of listener chemistry questions 02:04 — Correction: methane, propane, and household natural gas 04:01 — How European AC systems handle propane safely 05:47 — Could more chemistry-education episodes be coming? 07:33 — The overlooked women and stories of chemistry 09:20 — What careers involve organic chemistry? 12:20 — A science teacher tackles the chemistry Praxis exam 13:38 — Do apples and human skin use the same protective pigment? 15:22 — Resources for learning organic chemistry 16:32 — How do topical pain-relief gels work? 19:35 — The HIV medication that suddenly stopped working 20:52 — How one crystal can transform an entire batch References from the Episode: Thanks to our monthly supporters Sara Hull Dog Day Dan Bri . Summer Alden Amanda Raymond Kyle McCray Justine Ash Vince W Julie S. Heather Ragusa Autoclave Dorien VD Scott Beyer Jessie Reder J0HNTR0Y Cullyn R Erica Bee Elizabeth P Rachel Reina Letila Katrina Barnum-Huckins Suzanne Phillips Venus Rebholz Jacob Taber Brian Kimball Kristina Gotfredsen Timothy Parker Steven Boyles Chris Skupien Chelsea B Avishai Barnoy Hunter Reardon Support this podcast on Patreon Buy Podcast Merch and Apparel Check out our website at chemforyourlife.com Watch our episodes on YouTube Find us on Instagram, Twitter, and Facebook @ChemForYourLife Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Justin Abbatemarco talks with Dr. Irene Cortese about recent advances in the treatment of progressive multifocal leukoencephalopathy (PML), focusing on immune-based therapies like virus-specific T cells and immune checkpoint inhibitors.  Read the related article in The New England Journal of Medicine.  Disclosures can be found at Neurology.org.  Show transcript:  Dr. José Merino: This is José Merino, editor-in-chief of the Neurology Family of Journals. The Neurology Podcast provides practical information to neurologists and other clinicians to help them provide better care for their patients. Thanks for listening, and have a great week. Dr. Justin Abbatemarco: Hello and welcome. This is Justin Abbatemarco with the Cleveland Clinic here with Irene Cortese to discuss an update on progressive multifocal leukoencephalopathy treatment in light of a New England Journal of Medicine correspondence, Resolution of PML After Treatment with Virus-Specific T Cells and HCT. Irene directs the Experimental Immunotherapeutics Unit at NINDS. Hello and welcome. Dr. Irene Cortese: Hi, thank you for the invitation to join you today. Dr. Justin Abbatemarco: It's a pleasure to have you on and to talk about this expanding space in rare disease. And maybe if we could start off, can we just take an overview on how PML usually presents and why does it remain so difficult to treat? Dr. Irene Cortese: PML, or progressive multifocal leukoencephalopathy, is an opportunistic infection of the brain that is caused by the JC virus. And most of us carry this virus lifelong and without any symptoms, and it really only causes disease when the immune system is significantly compromised and loses the ability to keep it in check. And so when that happens, the virus can gain the ability to infect oligodendrocytes, and this can lead to the rapidly progressive demyelinating infection called PML. These lesions that develop in PML are typically located in the white matter, and they are most often multifocal. And this leads to the clinical manifestation of a combination of cortical and subcortical symptoms that evolve over weeks to months. And, unfortunately, if immune competence can't be restored quickly, then the disease is fatal within just a few months. And so that's really the core of the problem here, is that there is no effective direct antiviral treatment. And the only thing that works is restoring the immune system ability to control it, but that's often very difficult to do. When it's even possible, it's frequently just not even fast enough. And so you can see this even in situations where you'd think that we'd have an advantage, for example, in HIV-associated PML, where we do have effective antiretroviral therapy. Even there, restoring immune competence can sometimes just take too long relative to how quickly PML progresses. And so on top of all that, PML is really quite rare and is also remarkably heterogeneous because it can occur in very different patient populations from HIV to hematological malignancy to genetic immune deficiencies. And this rarity and heterogeneity really make both the diagnosis difficult and also treatment development quite difficult. Dr. Justin Abbatemarco: It's such a interesting story, and these different backgrounds really present different challenges. But at these last few years, this has been a success story in some way because we've seen so much effort and research into this rare disease space, which is encouraging. We mentioned this at the top, but there are immune checkpoint inhibitors that have at least been trialed for this T cell exhaustion to see if we can boost the immune system, and then more recently with your work around allogeneic-specific T cells to help clear the infection. What have you taken away from those updates? Dr. Irene Cortese: The biggest takeaway is that these two approaches, checkpoint inhibitors and Virus-Specific T Cells, have really transformed the way that we think about PML. So for decades, our only option was really to try to reverse the underlying immune suppressive condition and just hope that the immune system caught up in time. And now we have these two active strategies to try to speed this process up. Importantly, both these strategies have validated the same core hypothesis that even without a direct antiviral agent, we can improve PML outcomes by restoring effective antiviral immunity. And that said, each of these approaches has real limitations. So first of all, they don't work in all patients. And we have best estimates of success rates somewhere in the 50 to 60% range overall. With checkpoint inhibitors, the fundamental issue is that you're trying to unleash an immune response that has to already be there in some latent or exhausted form. For example, in patients with very advanced immune compromise where the T-cell compartment is essentially absent, there's just nothing left to invigorate, and so checkpoint blockade is really unlikely to help. And even when they do work, there is a real risk of exacerbating underlying autoimmune disease as well as the risk of leading to immune reconstitution inflammatory syndrome, or IRIS, where inflammation in the central nervous system of this immune system waking up and attacking the infection can actually lead to severe morbidity and even death in some patients. Virus-Specific T Cells have a whole different set of limitations. These are mostly practical and logistical at this point. Access is really the big one because there are only a handful of centers worldwide that can manufacture Virus-Specific T Cells. And so this just isn't something you can easily do everywhere or quickly. And also, biologically, every virus-specific T-cell product which is made from a different donor is essentially a different drug. And so it's really hard to predict how any given cell product will actually behave in a given patient. I should also mention that for both these approaches, they truly are still experimental. We don't have any controlled studies, and so most of what we're working from is really retrospective series and case reports. And we definitely have no head-to-head data. And so while we apply general principles estimating residual immune capacity or weighing the risk of exacerbating immune-mediated adverse events, we're really making individualized judgment calls rather than following an evidence-based algorithm. Dr. Justin Abbatemarco: And could you talk about those Virus-Specific T Cells? It's not something we use commonly in neurology. How do those work? And have they been used in other spaces successfully that we've been able to maybe apply some of those principles here? Dr. Irene Cortese: Yeah. So Virus-Specific T Cells were really first developed in the transplant setting, and they were essentially a way to bridge patients immediately following myeloablation. And in the period of time it took them to fully immune reconstitute a brand new immune system, it was a way to protect them from the common viral infections mostly that can develop in this time period and that led to such high morbidity and even mortality. And so the way this is done is that you basically take healthy lymphocytes from a healthy donor, and you can train them in vitro by ex vivo expansion and stimulation to basically become professional killers of the particular virus of interest so that, at the end of this expansion period, you basically have a enriched antiviral product that can be adoptively transferred to the patient recipient. And they may not last for a very long time, however, they can, especially with repeated infusions, provide the necessary immunity to bridge until definitive immune reconstitution is achieved. And so the initial experience with Virus-Specific T Cells was really against the various viruses that are so common in the post-transplant setting, like CMV, EBV, adenovirus, and also BK virus, which is a cousin, let's say, of the JC virus. And over time, the process for manufacturing Virus-Specific T Cells has become more and more streamlined. And so back as in 2015, 2017, we started to realize that perhaps these types of cell products might even be used to treat an acute infection and not just to administer in the setting of a planned transplant. And so essentially we've done exactly this, basically copied these manufacturing methods from the transplant world to make Virus-Specific T Cells against the JC virus and can then use them to treat PML. I should mention that BK virus is very similar in structure to the JC virus. And for that reason, what we learned early on when we started to apply Virus-Specific T Cells to the treatment of PML was that we could actually use Virus-Specific T Cells that were made against BK virus and successfully treat PML. More recent years, groups have been manufacturing JC virus-specific BST, but those BK Virus-Specific T Cells can still be used to treat PML. Dr. Justin Abbatemarco: That's really incredible. And it's so cool when we borrow things from these other fields to help inform rare diseases within neurology space. Maybe it's a perfect segue into the cases report in New England Journal of Medicine where you had two cases with inborn errors of immunity. You've utilized the strategy and then stem cell transplant. Walk us through those cases. What did you see? What did we learn from these that we can apply more broadly? Dr. Irene Cortese: Our paper really told the story of our experience of treating these two young men. Both of them had developed PML in the setting of an inborn error of immunity. One of them had DOCK8 deficiency, and he also had Sézary syndrome as a comorbid condition. And the second patient had a CD40 ligand deficiency. And for both these patients, we basically adopted the same strategy, which was to first try to gain control of the JC viral infection. And once that infection was actually under control, then we went ahead and proceeded to definitive treatment of their underlying genetic immune deficiency, which was transplant in their setting to correct the real root problem that they had. And what I think was perhaps most instructive in this experience is what happened after transplant in both cases. So transplant obviously involves a period of renewed immune vulnerability, and that's exactly when we feared that the PML might come back, even though we had been able to gain control, at least temporarily, using this adoptive transfer Virus-Specific T Cells. Fortunately, in these two cases, that didn't happen. And in fact, patient one actually developed IRIS shortly after engrafting with worsening neurological symptoms and also imaging that showed active inflammation, which responded well to steroids. And he's now years out with no evidence of PML or his prior malignancy, which was also treated by the transplant. The second patient's course was complicated by cryptogenic organizing pneumonia, or COP, which can happen in the post-transplant setting, and did require steroids. And this did cause a transient uptick in the JC viral copy number in the spinal fluid, but this resolved once the steroids were tapered. And this patient also is now several years out with only mild residual neurological deficits. So it's important that for both these patients, the transplant donors, in addition to undergoing collection for the transplant itself, they also underwent a collection to make extra rescue Virus-Specific T-Cell products that we had on hand just in case the PML relapsed post-transplant, which of course was not, in the end, needed. And so basically, the overall strategy for both these patients was sequential and deliberate. First to establish virus-specific immune control, and only then proceeding to the definitive but higher risk step of transplant with the safety net available in case virus reactivated during that post-transplant period. Dr. Justin Abbatemarco: The complexity of these cases, though, and the successful outcome is just incredible. And again, we don't always treat these level of patients, but most neurologists will see PML during their career. How do you think this helps inform this broader field of PML treatment in your mind? Dr. Irene Cortese: For me, these two cases really crystallized the idea of immune facilitation as a bridge rather than as a standalone endpoint. For example, in these two patients, Virus-Specific T Cells could not have led to a definitive cure because the underlying immune defect was still there, but they could buy time and control the virus long enough to get to something that could actually fix the underlying problem, which in this case was the transplant. And I'll be honest, proceeding to transplant in a patient with active or recent PML was really frightening. And clearly that is not an option or appropriate at all for the majority of patients with PML. So I guess that the broader lesson here is that Virus-Specific T Cells or potentially other immune-facilitating strategies might serve as a bridge to get us to the point where we either have a way to address that root cause of immune suppression or just buy us the time needed to recover from immune suppressive exposures and perhaps opens up the question of how we might use sequential strategies and combinations of strategies to optimize the care of these patients. Dr. Justin Abbatemarco: Really appreciate your paradigm of how you think about these cases in treatment, and yet you can have these short-term strategies to bridge patients to have an improved immune response to get this under control. Could we talk about other common examples? So we have natalizumab-induced PML cases, HIV-associated PML cases. How would you think about managing those, so outside of these inborn errors of immunity? Dr. Irene Cortese: Each PML patient is somewhat unique, and definitely the underlying condition that is driving the immune suppressed state is really critical in mapping out what we need to do. I think of HIV-associated PML or even natalizumab-related PML as being somewhat unique. Because unlike most other causes of PML, we actually do have clear and reliable ways to restore immune competence, so basically antiretroviral therapy in HIV infection or simply discontinuing the non-immune-depleting drug natalizumab in the case of natalizumab-related PML. And so this is obviously a real advantage compared to many of the other underlying conditions where there really is no good way to reverse that immune suppression at all. That said, in some patients, for example, with advanced AIDS and very low CD4 counts, immune reconstitution can still be very slow even when the HIV replication itself is well controlled. And so in a subset of patients, the PML can still really pace the recovery. And so we do sometimes need strategies to bridge that gap. And basically. we would consider the same immune restoration approaches that we've been talking about right now. There is an added layer of complexity here that's a bit more, let's say, unique to HIV-related PML or to the setting of natalizumab-related PML, which is that in both these cases, immune reconstitution is going to happen eventually. And when it does, then many of those patients do experience PML IRIS where the constituting immune response paradoxically worsens the neurological injury by attacking the infected tissue. And so this really needs to be watched for and managed typically with steroids. And certainly this risk of developing PML IRIS needs to be really considered if we are going to use strategies to boost or facilitate immune reconstitution in the setting of HIV infection or natalizumab-related PML. And we just have to be particularly mindful because there's already a very high likelihood of developing PML IRIS independently of getting that extra boost. Comparatively, in the setting of non-HIV-related PML or not in the setting of natilizumab treatment, I think that strategies like checkpoint inhibition and Virus-Specific T Cells have really been game-changing because, historically, these patients had no equivalent to antiretroviral therapy with no reliable path to reconstituting immunity. And we're really hoping that these approaches will start to bring the outcomes that we've seen, for example, among HIV-related PML and in the setting of natalizumab and PML to these other underlying conditions and achieve the same immune control and survival rates that are achieved in at least a substantial portion of these patients. Dr. Justin Abbatemarco: It's been so exciting. Again, the updates in this field when we really did... We had nothing to offer patients for so long and now to have conversations that are a little bit different. Can I ask you to peer around the corner? What does the future look like in your mind? Do you see other therapies that are potentially at play and maybe right now are there clinical trials that we could enroll patients so that we can help inform the field more broadly? Dr. Irene Cortese: Yeah. So I think that ways to facilitate and accelerate immune reconstitution have clearly been shown to be a valid strategy. And so what I expect and hope is that in the years to come, we'll learn to harness that better and learn to identify which patients are most likely to respond to particular types of strategies to facilitate immune reconstitution. It's really important, I would say, that patients participate in trials because the field really does lack controlled data and it lacks head-to-head comparisons. And so every patient enrolled in a trial or a well-structured registry is really contributing to how the next patient gets treated. And given just how rare and heterogeneous PML is, we're just not going to advance this field through isolated case reports alone. And so we really do need patients and their physicians to be willing to participate in structured and collaborative research. The Holy Grail is, of course, a direct antiviral agent that would really broaden our ability to treat patients and potentially also continue to treat whatever that underlying condition was that led them to the risk of PML in the first place, so, for example, patients receiving treatment for cancer or patients having an autoimmune disease that requires immune suppression. And so I am hopeful that eventually the direct antiviral will be identified. And along that line, what I can mention is there are certainly clinical trials that are ongoing. At NIH, we have an active natural history study from where we can funnel patients into various experimental treatment strategies, including Virus-Specific T Cells or checkpoint inhibitors. Or right now, we actually do have an ongoing trial of intravenous brincidofovir as a possible direct antiviral strategy. What I hope for the future is that we will find ways to really collaborate and to form national as well as international consortia so that we can accelerate the development of these treatments. Dr. Justin Abbatemarco: We have things we can do now, and then we can help inform care for our future patients as well. So these are great messages, and I can't thank you enough for coming on. Again, most of these developments have been under your guidance, and we appreciate your leadership in this space and helping to give us this insight into this really rare disease. For folks, they can check out the article. It's in the New England Journal of Medicine, Resolution of TML After Treatment with Virus-Specific T Cells and HCT. Irene, thank you for coming on. Dr. Irene Cortese: Thank you so much. Dr. Stacey Clardy: This is Stacey Clardy, your podcast editor. If you've enjoyed the podcast, please take a few moments to subscribe, rate, and review the Neurology Podcast through Apple Podcasts, Google Podcasts, Spotify, or wherever you listen. And remember, you can always head to neurology.orgpodcast for our full list of past episodes, or you can also search by keyword on your podcast app for any neurology-specific topics.

What are all these swabs for? Haven’t we been swabbed enough! This sweeping episode asks some silly questions about various kinds of STI tests and what those different swabs and samples can actually tell us. In the words of Aquaria, any hole is a goal! As a follow-up to our episode about cum, we’re on the journey of a fluid’s various paths. What are throat and rectal swabs looking for? Are different parts of the body associated with different STI risks? And how has the history of HIV stigma shaped the way we think about anal sex and transmission? Answering these questions with us is Callen-Lorde’s own Dr. Demetre Daskalakis. Hungry for more Sniffies’ Cruising Confessions? Follow Sniffies' Cruising Confessions: cruisingconfessions.com Try Sniffies: sniffies.com Follow Sniffies on Social: Instagram: instagram.com/sniffiesapp X: x.com/sniffiesapp TikTok: tiktok.com/@sniffiesapp Follow the hosts: Gabe Gonzalez: instagram.com/gaybonez Chris Patterson-Rosso: instagram.com/cprgivesyoulife Guest featured in this episode: Dr. Demetre Daskalakis: https://www.instagram.com/drdemetre/ See omnystudio.com/listener for privacy information.

Außerdem: Wie offen bin ich wirklich für Veränderungen? (12:50) // Mehr spannende Themen wissenschaftlich eingeordnet findet ihr hier: www.quarks.de // Habt ihr Feedback, Anregungen oder Fragen, die wir beantworten sollen? Dann meldet euch über Whatsapp oder Signal unter 0162 344 86 48 oder per Mail an quarksdaily@wdr.de. Von Sebastian Sonntag.

In response to rising HIV cases in New York City, PrEP4All and the Save HIV Funding Campaign will convene a Community Forum in partnership with NYU Law's Engelberg Center on Innovation Law & Policy. Once a national leader in ending the HIV epidemic, New York now faces stalled progress and increasing diagnoses — particularly in communities long disproportionately impacted — making this a critical moment for renewed urgency and leadership. This Town Hall will bring together candidates for New York's 12th Congressional District, alongside public health leaders and advocates, for a solutions-driven conversation on expanding PrEP access and strengthening prevention infrastructure. Designed as a high-visibility platform, the forum aims to drive concrete policy commitments and public accountability at a pivotal moment for HIV prevention. Candidates in attendance will include, Alex Bores Chris Diep Laura Dunn Dr. Wilneida Negron Karen Ortiz Nina Schwalbe Patrick Timmins Note: The event will be conducted in a strictly nonpartisan manner, with no endorsement of candidates or political parties

In 1968, one mother's public support for her gay son helped inspire the founding of PFLAG — Parents, Families, and Friends of Lesbians and Gays. Today, PFLAG has hundreds of U.S. chapters and an international network connecting families, friends, and allies for support, education, and advocacy. PFLAG Los Angeles Vice President Anthony Eftimeo speaks with This Way Out's Lucia Chappelle about what meaningful allyship looks like and how allies can help LGBTQ+ people and their families thrive. In the news this week, Turkish activists take to the streets as the right-wing government's anti-queer raids and arrests escalate, but the formerly right-wing Hungarian government will scrap its “no promo homo” law. Fiji sees a spike in HIV infections. There'll be no gender-affirming care for trans youth in North Dakota, but the city of Seattle, Washington expands civil protections with the times. Featured speakers: editor-in-chief of the LGBTI+ rights group Kaos GL Yildiz Tar, PFLAGLA VP Anthony Eftimeo, Lucia Chappelle Credits: Associate Producer Lucia Chappelle, Producer/ host Brian DeShazor, News writer Jeb Backe, the feature was produced by Brian DeShazor and Lucia Chappelle, NewsWrap reporters John Dyer the 5th and Melanie Keller. music: Dolly Parton and theme music was written and performed by Kim Wilson.

It was once a diagnosis widely believed to be an absolute death sentence, but much has changed since the earliest years of the AIDS epidemic. There have been tremendous advances in detection and treatment which have dramatically improved health outcomes for millions. Still, an estimated 1.2 million people in the U.S. are living with HIV, and 13% of them don’t know it. That gap is tied to barriers in access to testing, treatment, and ongoing care, and it continues to contribute to increases in new diagnoses. On today’s special edition of Closer Look with Rose Scott, we look beyond the disease itself to examine how stigma is also a factor. Our panel discusses efforts to confront and reduce stigma surrounding HIV/AIDS. If you or someone you know is in need of testing for HIV/AIDS, you can access these resources: AID Atlanta, Grady Healthcare, Cobb & Douglas Public Health, CVS Minute Clinic, AvitaCare Atlanta. Guests: Jerrell Hardnett, associate director of education & advocacy at GLAAD, and the author of GLAAD's sixth annual State of HIV Stigma Report Tim'm West, executive director of Rustin Institute Nicole Roebuck, Executive Director of AID Atlanta Pastor Eric Thomas, Saint Peter Missionary Baptist Church and a founder & President of Metro Atlanta Ministerial AllianceSee omnystudio.com/listener for privacy information.

In episode 88 of Going anti-Viral, Dr Elaine Abrams joins host Dr Michael Saag to discuss her career of research into vertical transmission of HIV and care for pregnant women, children, adolescents, and families. Dr Abrams is a Professor of Epidemiology and Pediatrics at Columbia University Medical Center and Senior Director of Research at ICAP at Columbia University in New York. An internationally recognized pediatrician, epidemiologist, and global health leader, she has more than 35 years of experience as a clinician, researcher, and public health practitioner in the prevention and treatment of HIV infection and associated infectious diseases. Dr Abrams and Dr Saag discuss the history and progress of preventing vertical HIV transmission and the impact of early studies like PACTG 076. They also discuss Dr Abrams's early work in Africa on HIV transmission and review the current understanding of breastfeeding and HIV transmission. They address the impact of the dismantling of USAID on global HIV prevention efforts and provide an outlook to the future for HIV elimination and global efforts.0:00 – Introduction 1:31 – First cases of vertical transmission of HIV and rates of transmission4:00 – Challenges faced during the early HIV epidemic in New York 9:16 – The landmark PACTG 076 study and its significance12:30 – Global expansion of HIV prevention efforts and treatment17: 03 – Engagement with HIV programs in Africa and lessons learned20:12 – Impact of program disruptions due to dismantling of USAID and future challenges24:47 – Current understanding of breastfeeding and HIV transmission28:44 – Future outlook for HIV elimination and global efforts__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

The rise, fall and rise of the most nonsensical conspiracy theory we've ever heard.Thanks to Gregg Gonsalves for helping us fact-check this episode! Support us:Hear bonus episodes on PatreonWatch Aubrey's documentaryBuy Aubrey's bookListen to Mike's other podcastGet Maintenance Phase T-shirts, stickers and moreLinks!Denying AIDS: Conspiracy Theories and Pseudoscience in a Post-COVID WorldImpure Science: AIDS, Activism, and the Politics of KnowledgeThe Duesberg PhenomenonAIDS Denialism Beliefs among People Living with HIV/AIDSHIV Denial in the Internet EraHIV Denial in the COVID EraHow COVID conspiracy theories led to an alarming resurgence in AIDS denialismThe Man Who Thought AIDS Was All In The MindAIDS "Dissident" Seeks RedemptionTruth and Heresy About AIDSDefending the boundaries of scienceJustice After AIDS DenialismAIDS Denialism vs. ScienceThe UnbelieverEstimating the lost benefits of ARV use in South AfricaConspiracy beliefs about HIV/AIDSAre HIV/AIDS Conspiracy Beliefs a Barrier to HIV Prevention Among African Americans?HIV causes AIDS: Koch's postulates fulfilledAIDS And The Scientific Governance Of Medicine In Post-Apartheid South AfricaThe DenialistsHas Duesberg a right of reply?Thanks to Doctor Dreamchip for our lovely theme song!Support the show

In part two of Red Eye Radio with Gary McNamara and Eric Harley, a Fox News poll shows the economy is hurting Trump and Republicans / Ron DeSantis weighs in on the economic reality of inflation / Ed Sheeran has to tow the antisemitic line / The HIV epidemic in Fiji / Troubled times for comedian Carrot Top For more talk on the issues that matter to you, listen on radio stations across America Monday-Friday 12am-5am CT (1am-6am ET and 10pm-3am PT), download the RED EYE RADIO SHOW app, asking your smart speaker, or listening at RedEyeRadioShow.com. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Watch every episode ad-free & uncensored on Patreon: https://patreon.com/dannyjones Baron Coleman is a trial lawyer turned political media personality who has done over 175 videos investigating the Charlie Kirk assassination. He hosts the  @realbaronpodcast . SPONSORS https://irestore.com/djp - Use code DJP for HUGE savings on iRestore. https://ethos.com/danny - Get up to $3 million in coverage in as little as 10 minutes. https://prizepicks.onelink.me/LME0/DANNY - Use code DANNY and get $150 if you win your first $5 lineup! https://hims.com/danny - Get simple online access to personalized & affordable care for hair loss, ED, weight loss & more. https://whiterabbitenergy.com/?ref=DJP - Use code DJP for 20% off. EPISODE LINKS @realbaronpodcast https://x.com/baroncoleman *NEW* DJP MERCH https://dannyjonespodcast.com Get paid to make clips from the show: https://discord.com/invite/dannyjones FOLLOW DANNY JONES https://www.instagram.com/dannyjones https://twitter.com/jonesdanny OUTLINE 00:00 - Erica Kirk's past doesn't add up 06:08 - Charlie Kirk's last text message 09:20 - How Google Trends predicted Charlie Kirk shooting 17:08 - Weird details about Thomas Crooks' shooting 21:38 - Most suspicious angle in Charlie Kirk case 24:24 - Why Tyler Robinson's parents would stay silent 30:15 - "Charlie Kirk was not shot with a gun" 36:34 - Joseph Scott Morgan's opinion on Charlie Kirk crime scene 43:37 - Mystery of Charlie Kirk's necklace 45:56 - Medical examiner's report on Charlie Kirk's neck 53:29 - TPUSA's response to Kirk's death 01:00:32 - The man who "discovered' Charlie Kirk 01:04:58 - Charlie Kirk's relationship with Israel 01:08:13 - The event that sealed Charlie Kirk's fate 01:11:11 - Tyler Robinson's confessions are nonsense 01:13:35 - The Egyptian plane in Utah 01:18:29 - HIV criminal defense cases 01:26:10 - HIV test kits are unreliable 01:31:31 - "Beyond a reasonable doubt" 01:33:48 - Lindsay Clancy seemed like a media operation 01:42:32 - We've been lied to about everything 01:47:38 - 1% chance we went to the moon 01:52:20 - Near 0% chance Tyler Robinson shot Kirk 01:56:45 - Charlie Kirk's bodyguard's suspicious signal 02:06:22 - The pastor back-stage with Charlie Kirk 02:14:24 - Making politics your identity 02:20:03 - Butler shooting changed Trump 02:28:21 - Hypernormalization & hyperspecialization 02:34:15 - The establishment is losing control 02:43:59 - Next steps in Charlie Kirk trial Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode of The Caring Economy, Toby Usnik speaks with Kyle Clifford, CEO of amfAR, about HIV research, philanthropy, leadership, and the changing funding landscape for medical science.Kyle is the first amfAR CEO to be openly living with HIV, bringing a deeply personal perspective to an organization whose research has helped shape the global response to the disease. He reflects on his career across business development, fundraising, City Harvest, The Ireland Funds, and amfAR, and talks about what it takes to keep long-term research moving when funding is uncertain. The conversation also covers private philanthropy, early-stage science, AI-enabled HIV research, and why backing ambitious work today can lead to breakthroughs far beyond HIV. A thoughtful conversation about science, purpose, and what it means to lead an organization whose mission is also part of your own life story.

Fiji is declaring an HIV emergency.See omnystudio.com/listener for privacy information.

Medication that helps prevent HIV transmission is readily available in Australia, including for temporary visa holders and those without Medicare. So why are some LGBTQI+ migrants missing out? - Лекарство, которое помогает предотвратить передачу ВИЧ, доступно в Австралии, в том числе для людей с временными визами и без Medicare. Почему же некоторые ЛГБТИК+ мигранты не могут им воспользоваться?#sbsaudiopodcast - Больше историй, интервью и новостей от SBS Russian доступно здесь.Слушайте программу на русском языке SBS по понедельникам, четвергам и субботам в 12 часов дня.Читайте нас в Facebook и Instagram и подпишитесь на наши подкасты по этой ссылке.

Those leading the fight against HIV in Fiji are also having to deal with dangerous drug practices and misinformation. The country's government has declared a national emergency in response to the virus, with an estimated one-in-sixty people infected. Dr Jason Mitchell, chair of Fiji's national HIV outbreak and cluster response taskforce, spoke to John Campbell.

In his weekly clinical update, Daniel Griffin and Vincent Racaniello are angered by the continuous reporting of measles deaths in the US and around the world, the Ebola outbreak in Uganda, changes in reporting of virus infection and vaccine recommendations, establishing an NIH research center on vaccine harms, Legionnaires at Yankee stadium and the first time in more than half a century reporting of an equine screwworm case, and how HHS may prevent more than half of US children from getting the COVID-19 vaccine this season before Dr. Griffin deep dives into recent statistics RSV, influenza, SARS-CoV-2 infections, efficacy and safety of the 2026-2027 COVID-19 vaccine, and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode   Unvaccinated Woman Likely Died of Measles Complications, Pa. County Coroner Says NY Times) Confirmed death of an 18-year old due to complications of measles (Facebook: Mifflin County Coroner's Office) CDC's new tracking method for measles deaths puzzles experts (CIDRAP) Kennedy to deliver keynote for anti-vaccine group he once led (STATNews) Exclusive: New NIH research center on vaccine harms takes shape (Science) US pediatricians report seeing fewer patients because of immigration enforcement worries (CIDRAP) Surgeon General Nominee Pledges Support for Vaccines in Senate Hearing (NY Times) CIDRAP Op-Ed: HHS is asking what to call vaccine recommendations. You have 4 days to weigh in. (CIDRAP) 21,000 Unvaccinated Children Are Not a Minor Problem, But a Warning Sign (GPEI) Researchers file First Amendment challenge to NIH grant screening (Science) Cooling towers at Yankee Stadium test positive for Legionnaires' in new cluster (NBC News) Legionnaires' Disease (NYC: Health) Dashboard SCREWWORM.Gov (USDA: Animal and Plant Health Inspection Service) CDC Activates Emergency Operations Center for New World Screwworm Response (CDC Newroom) Texas ranch horse becomes nation's first confirmed equine New World screwworm case (Houston Chronicle) Quick takes: Cautious optimism on Ebola, rare New World screwworm in a horse, HIV alert in Fiji (CIDRAP) Ebola dashboard (ebola.fyi) EBOLA: The Democratic Republic of the Congo, 2026 (WHO) Bundibugyo virus disease outbreak Democratic Republic of the Congo (WHO: Democratic Republic of Congo) Ebola Outbreak: Current Situation (CDC:Ebola) Notes from the Field: The First 100 Days of Five Ebola Outbreaks — Democratic Republic of the Congo, Uganda, and West Africa, 2007–2026  (CDC: MMWR) Notes from the Field: Characteristics and Monitoring of the 2026 Outbreak of Ebola Disease Caused by Bundibugyo Virus — Democratic Republic of the Congo, August 2026 (CDC:MMWR) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Big outbreak, bright lights…Measles Dashboard (South Carolina Department of Public Health) Utah measles outbreak response (Utah Department of Health and Human Services) Utah Measles Dashboard (Utah Department of Health and Human Services) Measles (VDH: Virginia Department of Health) Tracking Measles Cases in the U.S. (Johns Hopkins) HAP's Latest News Pa. Launches New Measles Dashboard (Hospital + HealthSystem Association of Pennsylvania) Measles (Commonwealth of Pennsylvania) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Measles (CDC: Measles Rubeola) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Measles in Bangladesh (microbeTV: TWIV) Suspected measles cases kill nearly 1,000 as Bangladesh struggles to contain outbreak (AP News) Measles Cases and Outbreaks (CDC: Rubeola) Laboratory Testing for Measles (CDC: Measles (Rubeola) Measles Clinical Diagnosis Fact Sheet (CDC: Measles (Rubeola) Measles Serology Testing (CDC: Measles (Rubeola) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Flu vaccine recommendations: Vaccines and Related Biological Products Advisory Committee March 12, 2026 Meeting Announcement (FDA) WHO updates all 3 viral strains to be included in fall flu shots (CIDRAP) FDA vaccine advisers recommend adding subclade K to fall shots (CIDRAP) Weekly surveillance report: clift notes (CDC FluView) OPTION 2: XOFLUZA $50 Cash Pay Option (xofluza) Early Antiviral Therapy in Pediatric Outpatients and Risk of Influenza-Related Hospitalization (Pediatrics) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) RSV Immunization Effectiveness and Safety for the 2026-2027 Respiratory Season (JAMA) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines (Moderna) Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season (novavax) Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine (Pfizer) FDA approves new COVID vaccines (CIDRAP) Covid Vaccines Delayed for Half of U.S. Children (NY Times) COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season (JAMA) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Reaching out to US house representative Letters read on TWiV 1358 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks!   Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Brittany Renee Williams was seven years old when she disappeared from Henrico County, Virginia, in 2000. She was living with the woman who ran Rainbow Kids, a home for children with serious medical conditions, and required ongoing treatment for HIV. But when Brittany vanished, nobody reported her missing.For more than two years, her Social Security and Medicaid benefits continued to be collected while conflicting stories were told about where she had gone. By the time investigators finally opened a missing-person case, the trail was already years old.Searches produced no remains, and no one has ever been charged in connection with her disappearance. More than twenty-five years later, Brittany's case remains open. Tonight, we tell her story. YouTube - https://www.youtube.com/@HauntedAmericanHistoryTikTok - @hah_podcasthauntedamericanhistory.comPatreon- ⁠⁠⁠⁠⁠⁠https://www.patreon.com/hauntedamericanhistory⁠⁠⁠⁠⁠⁠HAH DISCORD - https://discord.com/invite/bJdbpH3hQm Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This week we note and mourn the passing of pediatric cardiologist and thought leader Dr. Steven Lipshultz who passed on September 4, 2026. Dr. Lipshultz was one of the most significant cardiologists of the past half century and his contributions to the fields of pediatric cardiomyopathy, HIV cardiomyopathy and cardio-oncology were gigantic and meaningful. This week we turn back the clock and review a landmark work of Dr. Lipshultz from the Pediatric Cardiomyopathy Registry that was published in 2003 in the NEJM and we speak with 3 pediatric cardiomyopathy experts as well as friends and colleagues of Dr. Lipshultz - namely Dr. Neha Bansal of NYU, Dr. Daphne Hsu of the Albert Einstein College of Medicine and Dr. Joseph Rossano of the Children's Hospital of Philadelphia. Each shares their remembrances of this work and provide insights into the legacy of Dr. Lipshultz. doi: 10.1056/NEJMoa021715.

Stressed out and wondering where your sex drive went? You're not broken. You're just stuck in survival mode. In this episode, licensed sex therapist Dr. Holly Wood, PhD, joins us to unpack why stress is the ultimate libido killer and what to actually do about it. We dig into the real difference between spontaneous and responsive desire, why desire discrepancy is the #1 issue she sees in her practice, and how to stop internalizing your partner's low libido as a personal rejection.✨ Special Offers: ✨Splash Blanket! | Use code Jordan15ProDx Health | Use JordanDnelle to save 25%Happy V | use JORDANDNELLE to save 15%Thank you to our Sponsors: Splash Blanket, Prodx, Phex, Happy VJump to the Good Stuff:07:00 – Why stress traps you in "survival mode" and kills access to pleasure12:15 – Pre-workout, blood flow, and the lowest-stress window for sex14:37 – The real libido killers: resentment, fatigue, uneven mental load16:22 – Get out of your head and into your body17:22 – Why talking during sex is underrated25:00 – Spontaneous vs. responsive desire27:50 – Desire discrepancy is normal31:20 – "It's not about you" - reframing rejection and low desirePleasure Highlights:Stress doesn't just kill the mood; it hijacks your nervous system.Desire isn't one-size-fits-all.Desire discrepancy is normal, not a dealbreaker.Your partner's low desire usually isn't about you.Connect with Dr. Holly Wood, PhD:Instagram @DrHollyWoodPhD https://www.instagram.com/drhollywoodphd/YouTube @DrHollyWoodPhD https://www.youtube.com/@DrHollyWoodPhDWebsite: https://www.thehollywoodsexologist.com/Enhance your self-awareness by acknowledging and understanding your behavior patterns, and foster a deeper connection with your inner self. Get the Unleashing My Power: A Women's Empowerment and Gratitude Journal to reclaim your power through daily gratitude. Learn more HERE.Connect with Jordan D'Nelle:Facebook @‌jordandnelleInstagram @‌jordandnelleInstagram @‌TheVVVPodcastTikTok @‌jordandnelleYoutube @jordandnelleWebsite: Jordan D'Nelle⁠⁠Email: JordanDnelle@VaginasVulvasandVibrators.comLove this Episode? Join the Patreon: patreon.JordanDnelle.comLeave a review on iTunes.Subscribe & Follow on socials!Listen and Subscribe to the Podcast:Apple PodcastSpotify PodcastYoutube @jordandnelle*Disclaimer: This podcast is for informational and/or entertainment purposes only and is not a substitute for medical advice, diagnosis, or treatment. The views and opinions expressed are my own, or those of my guests, and do not necessarily reflect the views of any organizations or institutions with which I am affiliated.Vaginas, Vulvas, and Vibrators, the unapologetic women's sexual wellness podcast, normalizing pleasure, bodies, and sexual health through expert, shame-free conversations.PhexxINDICATIONPhexx® is an on-demand prescription birth control used to prevent pregnancy. Phexx is not effective when used after sex.IMPORTANT SAFETY INFORMATIONRare cases (0.36%) of bladder and kidney infection have been reported. If you have a history of urinary tract problems that keep coming back, you should not use Phexx.Contact your healthcare provider if you are experiencing genitourinary side effects such as vaginal burning, itching, discharge, genital discomfort (including in male partners), yeast infection, urinary tract infection or bacterial vaginosis.Phexx does not protect against any sexually transmitted infections, including HIV. Avoid using Phexx with a vaginal ring.Avoid Phexx if you or your sexual partner is allergic to lactic acid, citric acid, potassium bitartrate, or any of the Ingredients in Phexx. Stop using Phexx If you develop an allergic reaction.For more information about Phexx, talk to your healthcare provider and see full Product Informationat www.phexx.com.Please report side effects by contacting Evofem Biosciences® toll-free at 1-833-EVFMBIO or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.EVFM-PHX-000068